Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: Detailed safety analysis from a phase 3 trial in patients with advanced melanoma

Cancer

Volumn 119, Issue 9, 2013, Pages 1675-1682

  Weber, Jeffrey S ^a   Dummer, Reinhard ^b   De Pril, Veerle ^c   Lebbé, Celeste ^d   Hodi, F Stephen ^e  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c BRISTOL MYERS SQUIBB   (United States)

^d SAINT LOUIS HOSPITAL   (France)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

adverse drug events; immune system phenomenon; ipilimumab; mechanism of action; metastatic melanoma

Indexed keywords

ANALGESIC AGENT; ANTACID AGENT; ANTIANEMIC AGENT; ANTICOAGULANT AGENT; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD DERIVATIVE; CORTICOSTEROID; DACARBAZINE; DIURETIC AGENT; GASTROINTESTINAL AGENT; GLYCOPROTEIN 100 MELANOMA ANTIGEN VACCINE; HERBACEOUS AGENT; HYDROCORTISONE; IPILIMUMAB; LAXATIVE; LEVOTHYROXINE; MELANOMA VACCINE; MINERAL; PLACEBO; PREDNISOLONE; PREDNISONE; TEMOZOLOMIDE; THYROXINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ALGORITHM; ARTICLE; CACHEXIA; COLITIS; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DIARRHEA; DRUG FATALITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FEMALE; FEVER; GUILLAIN BARRE SYNDROME; HUMAN; HYPOPHYSITIS; HYPOPITUITARISM; IMMUNOPATHOLOGY; INFECTION; INTESTINE PERFORATION; KIDNEY FAILURE; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MYELOFIBROSIS; NEUTROPHILIA; PATIENT MONITORING; PERITONITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEPTIC SHOCK; SEPTICEMIA; SIDE EFFECT; SKIN DISEASE; SYNDROME; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; VASCULAR LEAK SYNDROME;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNE SYSTEM; MALE; MELANOMA; MIDDLE AGED; PLACEBOS;

EID: 84876678621     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27969     Document Type: Article

References (20)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-723.
2. Lens M, Ferrucci PF, Testori A,. Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings. Recent Pat Anticancer Drug Discov. 2008; 3: 105-113.
3. Margolin K,. Moving forward with immunotherapy: the rationale for anti-CTLA-4 therapy in melanoma. Commun Oncol. 2008; 5: 367-374.
4. Di Giacomo AM, Biagioli M, Maio M,. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol. 2010; 37: 499-507.
5. Bristol-Myers Squibb. YERVOY (ipilimumab) summary of product characteristics. Braine-l'Alleud, Belgium: Bristol-Myers Squibb; 2011. Available at: http://www.yervoy.co.uk/smpc/. Accessed January 13, 2013.
6. O'Day S, Weber JS, Wolchok JD, et al. Effectiveness of treatment guidance on diarrhea and colitis across ipilimumab studies [abstract]. J Clin Oncol. 2011; 28 (suppl). Abstract 8554.
7. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006; 24: 2283-2289.
8. Harmankaya K, Erasim C, Koelblinger C, et al. Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than 2 years following ipilimumab therapy. Med Oncol. 2010; 28: 1140-1144.
9. Lorigan P, Sosman J, Haanen JB, et al. Clinical response to ipilimumab: effect of systemic corticosteroids used to manage immune-related adverse events (irAEs) [abstract]. Ann Oncol. 2010; 21: viii404. Abstract 1331P.
10. Hinrichs CS, Palmer DC, Rosenberg SA, Restifo NP,. Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells. J Immunother. 2005; 28: 517-524.
11. Franchimont D,. Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann N Y Acad Sci. 2004; 1024: 124-137.
12. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012; 13: 459-465.
13. Weber JS, Kahler KC, Hauschild A,. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012; 30: 2691-2697.
14. Lebbe C, O'Day SJ, Chiarion-Sileni V, et al. Analysis of the onset and resolution of immune-related adverse events during treatment with ipilimumab in patients with metastatic melanoma [abstract]. Paper presented at: Perspectives in Melanoma XII; October 2-4, 2008; Scheveningen/The Hague, Netherlands. Oral Abstract O-015.
15. Kahler KC, Hauschild A,. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. J Dtsch Dermatol Ges. 2011; 9: 277-286.
16. Klein O, Ebert LM, Nicholaou T, et al. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res. 2009; 15: 2507-2513.
17. Berman D, Parker SM, Siegel J, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma [serial online]. Cancer Immun. 2010; 10: 11.
18. Izcue A, Coombes JL, Powrie F,. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev. 2006; 212: 256-271.
19. Sarnaik AA, Yu B, Yu D, et al. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res. 2011; 17: 896-906.
20. Lin R, Yellin MJ, Lowy I, Safferman A, Chin K, Ibrahim R,. An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: prevention of gastrointestinal perforation and/or colectomy [abstract]. J Clin Oncol. 2008; 26 (suppl). Abstract 9063.